Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy

被引:11
|
作者
Eitel, Tamara [1 ]
Zeiner, Kim Nikola [1 ]
Assmus, Katharina [1 ]
Ackermann, Hanns [2 ]
Zoeller, Nadja [1 ]
Meissner, Markus [1 ]
Kaufmann, Roland [1 ]
Kippenberger, Stefan [1 ]
Valesky, Eva Maria [1 ]
机构
[1] Goethe Univ Frankfurt, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
[2] Goethe Univ Frankfurt, Dept Biostat & Math Models, Frankfurt, Germany
来源
WORLD ALLERGY ORGANIZATION JOURNAL | 2021年 / 14卷 / 05期
关键词
Hymenoptera venom allergy; Immunotherapy; Sting challenge; Quality of life; DEBILITATING BELIEFS; EMOTIONAL DISTRESS; HOSPITAL ANXIETY; DEPRESSION SCALE; INSECT; EPIDEMIOLOGY; VERSION; HADS;
D O I
10.1016/j.waojou.2021.100536
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients' quality of life (QoL). Besides carrying emergency medication, venom specific immunotherapy (VIT) exists as a causal treatment of allergy. Objective: This study aimed to examine QoL, anxiety, depression, and physical and mental health in patients allergic to hymenoptera venom before and during VIT and the impact of a tolerated sting challenge (SC). Methods: Between July 2017 and August 2017, 142 patients with venom allergy were analyzed using validated questionnaires as the: Vespid Allergy Quality for Life Questionnaire" (VQLQ-d), the "Hospital Anxiety and Depression Scale" (HADS-D) and the "Short Form 36" (SF-36).To evaluate the impact of VIT and SC on the QoL, patients were divided into 3 groups: (A) VIT and tolerated SC (n =45), (B) VIT before carrying out SC (n = 73), and (C) therapy-na & iuml;ve before VIT (n = 20). Further parameters like gender, age, insect species, and severity of the anaphylactic reaction were assessed. Results: A significant correlation between the health-related QoL and the parameters of gender and state of treatment was seen. Especially male patients, as well as patients allergic to yellow jacket venom, benefit from a SC in terms of a significant increase in their QoL. In the total study cohort, a clear trend was observed towards a higher QoL in patients under VIT who tolerated a SC. Overall, neither the patients' age nor the insect species exerted a relevant influence on QoL, depression or anxiety. However, women showed a lower QoL combined with higher anxiety and depression scores than men. Conclusion: Immunotherapy leads to an improved QoL, which can be further increased by a SC. A tolerated SC conceivably reassures the patients by objectifying the treatment success. Female patients appear to have a stronger impaired QoL per se. Taken together, a SC can be performed during VIT to strengthen the patients' QoL.
引用
收藏
页数:13
相关论文
共 50 条
  • [11] IMMUNOTHERAPY FOR ALLERGY TO HYMENOPTERA VENOM
    VALENTINE, M
    REVUE FRANCAISE D ALLERGOLOGIE ET D IMMUNOLOGIE CLINIQUE, 1983, 23 (02): : 65 - 68
  • [12] VENOM SPECIFIC IGE AND IGG ANTIBODIES IN HYMENOPTERA STING SENSITIVE PATIENTS BEFORE AND AFTER VENOM IMMUNOTHERAPY
    YMAN, L
    SMEDGARD, G
    SCHRODER, H
    ANNALS OF ALLERGY, 1981, 47 (02): : 130 - 131
  • [13] Quality-of-life in Portuguese hymenoptera venom allergic patients on venom immunotherapy
    Santa, C.
    Barreira, P.
    Moreira Da Silva, J.
    Lopes, I
    ALLERGY, 2018, 73 : 114 - 115
  • [14] RUSH VENOM IMMUNOTHERAPY - A 3-DAY PROGRAM FOR HYMENOPTERA STING ALLERGY
    NATAF, P
    GUINNEPAIN, MT
    HERMAN, D
    CLINICAL ALLERGY, 1984, 14 (03): : 269 - 275
  • [15] Insect sting allergy and venom immunotherapy
    Golden, DBK
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2006, 96 (02) : S16 - S21
  • [16] Hymenoptera venom allergy: work disability and occupational impact of venom immunotherapy
    Paolocci, Giulia
    Folletti, Ilenia
    Toren, Kjell
    Muzi, Giacomo
    Murgia, Nicola
    BMJ OPEN, 2014, 4 (08):
  • [17] Selected socio-demographic factors and quality of life of patients with hymenoptera venom allergy treated with immunotherapy
    Szynkiewicz, E.
    Graczyk, M.
    Wozniewicz, A.
    Bartuzi, Z.
    Zbikowska, M.
    Magdalena, Z-G
    ALLERGY, 2015, 70 : 430 - 430
  • [18] Impact of Hymenoptera venom allergy and the effects of specific venom immunotherapy on mast cell metabolites in sensitized children
    Cichocka-Jarosz, Ewa
    Sanak, Marek
    Szczeklik, Andrzej
    Brzyski, Piotr
    Pietrzyk, Jacek J.
    ANNALS OF AGRICULTURAL AND ENVIRONMENTAL MEDICINE, 2014, 21 (02) : 294 - 301
  • [19] Health-related quality of life in Polish adolescents with Hymenoptera venom allergy treated with venom immunotherapy
    Cichocka-Jarosz, Ewa
    Brzyski, Piotr
    Swiebocka, Ewa
    Lange, Joanna
    Tobiasz-Adamczyk, Beata
    Lis, Grzegorz
    Jedynak-Wasowicz, Urszula
    Kulus, Marek
    Kaczmarski, Maciej
    Malaczynska, Teresa
    Klajna-Kraluk, Barbara
    Breborowicz, Anna
    Kycler, Zdzislawa
    Pietrzyk, Jacek J.
    ARCHIVES OF MEDICAL SCIENCE, 2012, 8 (06) : 1076 - 1082
  • [20] Honeybee venom allergy: Immunoblot studies in allergic patients after immunotherapy and before sting challenge
    Jeep, S
    Paul, M
    Muller, U
    Kunkel, G
    ALLERGY, 1996, 51 (08) : 540 - 546